Concepedia

7108 Phase II study of IMC-1121B in patients with metastatic renal cell carcinoma (mRCC) following failure of VEGFR-2 tyrosine kinase inhibitor (TKI) therapy: interim results (IMCL CP12–0605/NCT00515697)

Jacob Garcia, G. R. Hudes, Toni K. Choueiri, Walter M. Stadler, L. Wood, Shailender Bhatia, Hagop Youssoufian, E.K. Rowinsky, Jazmin Schwartz, J.A. Thompson

European Journal of Cancer Supplements · 2009 · 14 citations · 0 references

Concepts

MedicineOncologyMetastasisMolecular OncologyTumor ProgressionKidney CancerMetastatic Disease TreatmentRenal Cell CarcinomaTyrosine Kinase InhibitorsMetastatic Kidney CancerMetastatic Renal Cell Carcinoma TherapyPhase Ii InvestigationRenal MalignancyStudy PhaseTyrosine Kinase Inhibitor PharmacokineticsVascular Endothelial Growth Factor InhibitionVegfr Inhibitors